PD-1/PD-L1抑制剂在治疗恶性黑色素瘤中引起白癜风样脱色的机制及研究进展

近年来，越来越多的肿瘤患者从免疫检查点抑制剂（ICPIs）中获得了显著疗效。其中，程序性细胞死亡受体-1/配体-1（PD-1/PD-L1）抑制剂是第二代ICPIs，已被批准用于多种晚期恶性肿瘤的治疗。随着其广泛使用，免疫相关不良反应（irAEs）也逐渐引起人们的关注，白癜风就是其中一种，尤其在恶性黑色素瘤患者治疗中较多出现。本文对恶性黑色素瘤患者使用PD-1/PD-L1免疫抑制剂引起白癜风样脱色的发生机制进行综述，旨在为阐明PD-1/PD-L1与免疫相关不良反应的关系提供可能的理论依据。

Mechanism and Research Progress of PD-1/PD-L1 Inhibitors Caused Vitiligo Like Discoloration in the Treatment of Malignant Melanoma

In recent years, more and more tumor patients treated with immune checkpoint inhibitors (ICPIs) showed significant effects. Among them, programmed cell death-1/ligand-1 (PD-1/PD-L1) inhibitors are second-generation ICPIs, which have been approved for the treatment of various advanced malignant tumors. With their widespread use, immune-related adverse events (irAEs) have gradually attracted people’s attention and vitiligo is one of them, especially in the treatment of patients with malignant melanoma. This article will review the mechanism of vitiligo like discoloration caused by the use of PD-1/PD-L1 immunosuppressants in patients with malignant melanoma, aiming to provide a possible theoretical basis for clarifying the relationship between PD-1/PD-L1 and immune-related adverse reactions.